IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PUOTI, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.961
AS - Asia 3.200
EU - Europa 2.402
SA - Sud America 494
AF - Africa 66
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 13
Totale 13.156
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.885
CN - Cina 1.205
SG - Singapore 1.054
UA - Ucraina 748
DE - Germania 421
BR - Brasile 420
HK - Hong Kong 356
FI - Finlandia 229
IT - Italia 192
GB - Regno Unito 159
FR - Francia 158
IN - India 140
VN - Vietnam 139
TR - Turchia 129
RU - Federazione Russa 118
IE - Irlanda 117
PL - Polonia 113
CA - Canada 44
BD - Bangladesh 41
SE - Svezia 41
AR - Argentina 26
ZA - Sudafrica 25
IQ - Iraq 22
MX - Messico 21
JP - Giappone 19
AU - Australia 16
BE - Belgio 16
NL - Olanda 15
PK - Pakistan 15
EU - Europa 13
VE - Venezuela 13
LT - Lituania 12
SA - Arabia Saudita 12
EC - Ecuador 11
AT - Austria 10
CO - Colombia 10
ES - Italia 10
UZ - Uzbekistan 10
IR - Iran 9
NG - Nigeria 8
CL - Cile 7
KE - Kenya 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
IL - Israele 6
MA - Marocco 5
AZ - Azerbaigian 4
BG - Bulgaria 4
DZ - Algeria 4
HU - Ungheria 4
ID - Indonesia 4
LB - Libano 4
MU - Mauritius 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
RS - Serbia 4
TN - Tunisia 4
CZ - Repubblica Ceca 3
EG - Egitto 3
JO - Giordania 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
PH - Filippine 3
SK - Slovacchia (Repubblica Slovacca) 3
AL - Albania 2
BY - Bielorussia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
JM - Giamaica 2
KG - Kirghizistan 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
PY - Paraguay 2
RO - Romania 2
AO - Angola 1
BF - Burkina Faso 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
EE - Estonia 1
ET - Etiopia 1
GY - Guiana 1
HN - Honduras 1
LK - Sri Lanka 1
LR - Liberia 1
LY - Libia 1
MK - Macedonia 1
NO - Norvegia 1
PS - Palestinian Territory 1
QA - Qatar 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 13.156
Salva come PNG Salva come JPEG
Città #
Woodbridge 766
Ashburn 695
Fairfield 665
Jacksonville 553
Singapore 537
Houston 485
Hong Kong 356
Ann Arbor 336
Wilmington 335
Cambridge 310
Seattle 304
San Jose 277
Nanjing 228
The Dalles 228
Princeton 193
Chandler 177
Beijing 172
Los Angeles 117
Dublin 116
Helsinki 113
Warsaw 112
New York 103
Istanbul 102
Lauterbourg 98
Nanchang 90
Dearborn 80
Moscow 70
Shenyang 59
Des Moines 55
Ho Chi Minh City 50
Changsha 49
Buffalo 48
Munich 47
San Diego 46
Shanghai 46
Jinan 43
Tianjin 43
Hebei 41
São Paulo 40
Jiaxing 36
Lancaster 33
Milan 33
San Francisco 33
Redondo Beach 32
Brescia 31
London 31
Washington 28
Chennai 22
Orem 21
Verona 21
Hanoi 20
Kunming 20
Santa Clara 19
Tokyo 19
Toronto 19
Brooklyn 17
Chicago 17
Hangzhou 17
Brussels 16
Charlotte 16
Dallas 16
Lanzhou 16
Taizhou 16
Council Bluffs 15
Kocaeli 15
Rio de Janeiro 15
Zhengzhou 15
Guangzhou 14
Brasília 13
Johannesburg 13
Leawood 13
San Mateo 13
Stockholm 12
Denver 11
Haikou 11
Monmouth Junction 11
Norwalk 11
Atlanta 10
Augusta 9
Belo Horizonte 9
Boston 9
Campinas 9
Curitiba 9
Delhi 9
Manchester 9
Ningbo 9
Nuremberg 9
Porto Alegre 9
Abuja 8
Ardabil 8
Melbourne 8
New Delhi 8
Tashkent 8
Turku 8
Dhaka 7
Frankfurt am Main 7
Haiphong 7
Hefei 7
Mexico City 7
Montreal 7
Totale 9.106
Salva come PNG Salva come JPEG
Nome #
A meta-analysis of epidemiological studies on the combined effect of hepatitis-B and -C virus infections in causing hepatocellular carcinoma. 207
Use of brain MRI in manganese exposure 204
Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial 196
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients 191
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 176
Antiretroviral drugs and liver injury. 171
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 170
Alcohol and coffee drinking and smoking habit among subjects with HCV infection. 167
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 166
Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. 165
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 165
Coinfezione HIV/HBV in Burkina Faso, Africa Occidentalele 159
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. 153
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 153
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 153
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 152
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 151
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. 148
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 148
Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and Human Immunodeficiency Virus. 147
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. 142
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel 142
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 142
Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients. 141
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy. 141
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. 141
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. 133
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia 132
Polymorphic immune restoration syndrome after effective HAART 131
Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV 130
Care of patients with hepatitis C and HIV co-infection. 129
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 129
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 128
Mortality for liver disease in patients with HIV infection: a cohort study 128
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 127
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: disegno dello studio. 126
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: risultati del primo anno di attività. 126
Natural history of chronic hepatitis B in co-infected patients. 125
Studio di affidabilità sul consumo di alcol, caffè e abitudine al fumo in pazienti HCV postivi. 123
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 123
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study 122
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C?A gender-oriented analysis. 122
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. 122
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. 120
Insulino-resistenza in pazienti HCV positivi sottoposti a trattamento antivirale in uno studio di coorte multicentrico: dati preliminari. 120
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 120
Co-infezione HIV-HCV e dislipidemie in corso di Highly Active Antiretroviral Therapy (HAART) 120
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. 119
Indagine sulla suscettibilità genetica nella risposta al trattamento antivirale di soggetti con epatite cronica da virus c attraverso uno studio di coorte multicentrico: disegno dello studio. 119
Treating hepatitis C virus in HIV patients: are side effects a real obstacle? 118
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. 118
HIV/HCV co-infection: natural history. 118
Statements from the Taormina expert meeting on occult hepatitis B virus infection. 117
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. 116
Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. 116
The attributable risk of hepatocarcinoma for the Hepatitis B and C virus infections in a high-incidence area in North Italy: a case-control study. 115
Ruolo dell'infezione occulta da virus dell'epatite B nell'evoluzione dell'epatite cronica da virus C attraverso uno studio di coorte multicentrico: dati preliminari. 115
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. 115
Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? 113
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 113
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. 113
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 113
Hepatitis B Virus Co-infection in Human Immunodeficiency Virus- infected Subjects 112
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. 112
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 112
HCV chronic hepatitis in patients with HIV: clinical management issues 110
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? 110
Management of hepatitis C in human immunodeficiency virus-infected patients. 110
Targeted screening for viral epatiti in an italian community of 100.000 inhabitants 110
Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. 110
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 109
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. 109
The burden of HIV and hepatitis C virus coinfection. 109
Hepatitis viruses coinfections, antiretrovirals hepatotoxicity and risk of death in HIV infected patients: a prospective cohort study 108
Impact of hepatitis C virus infection on lifestyle. 108
The use of molecular assays in the management of viral hepatitis. 108
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection-statements of the First Italian Consensus Workshop. 108
Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 108
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 107
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. 106
Insulin resistance is not a relevant predictor of sustaned virologic response (SVR) in chronic hepatitis c (CHC) patients treated with pegylated interferon (peg-ifn) and ribavirin. 106
The T-cell receptor repertoires expressed by CD4+ and CD4- large granularlymphocytes derived from the same patients suggest the persistent action of animmune-mediated selection process 106
Comment to the Editorial: Liver biopsy in HIV-infected pateints with chronic hepatitis C: pros and cons, by V. Soriano and J. Garcia Samaniego 105
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 103
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. 102
Co-infezione HIV-HCV e dislipidemie in corso di terapia antiretrovirale ad elevata efficacia (HAART) 101
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 97
Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy 96
I Data-Base clinici e la sorveglianza degli eventi avversi alla HAART: il Progetto MASTER 94
Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) 94
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome 93
Hepatotoxicity associated with non nucleoside reverse trasciptase inhibitors (NNRTI) in 427 adults infected with Human Immunodeficiency Virus. 91
HCV infection: pathogenesis, clinical manifestations and therapy. 90
Occult Hepatitis B virus and hepatocellular carcinoma: a case-control study. 90
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3 89
Risk of developing specific AIDS-defining illnesses in patients coinfected withHIV and hepatitis C virus with or without liver cirrhosis 85
Pathogenesis of liver damage in HCV-HIV patients. 84
Hepatitis C viral kinetics in HIV co-infected patients during combination treatment with interferon and ribavirin 82
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. 78
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. 78
Totale 12.395
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.354
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.354
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021344 0 0 0 0 0 0 0 0 0 110 196 38
2021/2022834 52 128 1 46 3 46 40 55 35 119 86 223
2022/2023654 112 8 10 31 49 207 0 70 90 7 31 39
2023/2024786 42 16 71 81 45 141 31 36 199 14 2 108
2024/20251.702 8 4 7 237 213 158 156 39 150 148 372 210
2025/20262.988 352 484 166 395 382 237 532 113 152 175 0 0
Totale 13.262